ConductScience.org, home

Paper · 35534455

Targeting double-strand break indel byproducts with secondary guide RNAs improves Cas9 HDR-mediated genome editing efficiencies.

Bodai Z and 3 others. Nat Commun, 2022. Cited by 27 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Targeting double-strand break indel byproducts with secondary guide RNAs improves Cas9 HDR-mediated genome editing efficiencies. Papers, record 35534455. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35534455

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Targeting double-strand break indel byproducts with secondary guide RNAs improves Cas9 HDR-mediated genome editing efficiencies.
PubMed
Journal
Nat Commun
PubMed
Year
2022
PubMed
Publication types
Journal Article, Research Support, U.S. Gov't, Non-P.H.S., Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
27
iCite
Relative citation ratio, by iCite
1.65
iCite
Revised in PubMed
2026-01-27
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Bodai ZZsolt
2Bishop ALAlena L
3Gantz VMValentino Mhttps://orcid.org/0000-0003-2453-0711
4Komor ACAlexis Chttps://orcid.org/0000-0001-5043-0998

Source PubMed

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Gene EditingMajor topic
Animals
CRISPR-Cas Systems
DNA End-Joining Repair
Mammals
Recombinational DNA Repair
RNA, Guide, CRISPR-Cas Systems

Source PubMed

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
DP5 OD023098NIH HHSUnited StatesDP5OD023098PubMed and NIHNIH RePORTER
R01 AI162911NIAID NIH HHSUnited StatesR01AI162911PubMed and NIHNIH RePORTER

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References54

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
127,120,160Efficient introduction of specific homozygous and heterozygous mutations using CRISPR/Cas9.Nature2016https://conductscience.org/library/papers/27120160PubMed
226,735,016High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects.Nature2016https://conductscience.org/library/papers/26735016PubMed
328,985,763Crossing enhanced and high fidelity SpCas9 nucleases to optimize specificity and cleavage.Genome Biol2017https://conductscience.org/library/papers/28985763PubMed
430,271,937Increasing Cas9-mediated homology-directed repair efficiency through covalent tethering of DNA repair template.Commun Biol2018https://conductscience.org/library/papers/30271937PubMed
525,184,501Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation.Nat Biotechnol2014https://conductscience.org/library/papers/25184501PubMed
631,634,902Search-and-replace genome editing without double-strand breaks or donor DNA.Nature2019https://conductscience.org/library/papers/31634902PubMed
726,789,497Enhancing homology-directed genome editing by catalytically active and inactive CRISPR-Cas9 using asymmetric donor DNA.Nat Biotechnol2016https://conductscience.org/library/papers/26789497PubMed
823,907,390Optimization of scarless human stem cell genome editing.Nucleic Acids Res2013https://conductscience.org/library/papers/23907390PubMed
928,931,002Enhanced proofreading governs CRISPR-Cas9 targeting accuracy.Nature2017https://conductscience.org/library/papers/28931002PubMed
1025,798,939Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining.Nat Biotechnol2015https://conductscience.org/library/papers/25798939PubMed

Cited by18

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 27 citations.

PMIDTitleJournalYearIn PapersSource
42,486,986Efficient and precise programmable DNA knock-in without double-strand breaks.Nature2026https://conductscience.org/library/papers/42486986PubMed
42,353,300CRISPR Gene Tagging for Illuminating Endogenous Protein Dynamics.Int J Mol Sci2026https://conductscience.org/library/papers/42353300PubMed
42,306,789Fundamentals and emerging frontiers in p53-targeted drug development.Biochem Biophys Rep2026https://conductscience.org/library/papers/42306789PubMed
42,261,595Harnessing Deep Learning Models for Guide RNA Optimization and Off-Target Prediction in CRISPR Systems.Biotechnol J2026https://conductscience.org/library/papers/42261595PubMed
41,445,195Transient muscle expression of mitoARCUS in mice leads to sustained reductions in pathogenic mtDNA and reduces fatigability.Mol Ther2026https://conductscience.org/library/papers/41445195PubMed
41,365,890Efficient high-precision transgene knock-in by Recombinases (Redα/β)-enhanced DNA integration-CRISPR-Cas9 (RED-CRISPR).Nat Commun2025https://conductscience.org/library/papers/41365890PubMed
41,361,167Search-and-remove genome editing allows selection of cells by DNA sequence.Nat Commun2025https://conductscience.org/library/papers/41361167PubMed
40,156,857Precision genome editing and in-cell measurements of oxidative DNA damage repair enable functional and mechanistic characterization of cancer-associated MUTYH variants.Nucleic Acids Res2025https://conductscience.org/library/papers/40156857PubMed
38,877,530CRISPR/Cas9 gene editing: a novel strategy for fighting drug resistance in respiratory disorders.Cell Commun Signal2024https://conductscience.org/library/papers/38877530PubMed
38,255,224Increasing Gene Editing Efficiency via CRISPR/Cas9- or Cas12a-Mediated Knock-In in Primary Human T Cells.Biomedicines2024https://conductscience.org/library/papers/38255224PubMed

1 to 10 of 18

See all 18 cited by

Genes20

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/35534455

GET https://conductscience.org/api/papers/v1/35534455/references?page=2